



FORM PTO-1449 (Rev. 10-2002) and B (modified PTO/SB/08)				APPLICATION NO.: 10/023,909	ATTY. DOCKET NO.: C1039.70058US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 18, 2001	CONFIRMATION NO.: 8458
				APPLICANT: Davis et al.	
Sheet	1	of	2	GROUP ART UNIT: 1648	EXAMINER: Jeffrey S. Parkin

**U.S. PATENT DOCUMENTS**

Examiner's Initials <sup>a</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A262	7,354,711	B2	Macfarlane	04-08-2008
	A263	2003-0176389	A1	Raz et al.	09-18-2003
	A264	2004-0006010	A1	Carson et al.	01-08-2004
	A265	2005-0238660	A1	Babiuk et al.	10-27-2005
	A266	2007-0258994	A1	Van Nest et al.	11-08-2007
	A267	2008-0026011	A1	Krieg et al.	01-31-2008
	A268	2008-0031936	A1	Krieg et al.	02-07-2008
	A269	2008-0045473	A1	Uhlmann et al.	02-21-2008

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials <sup>a</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B43	WO	97/40163	A1	Colpan et al.	10-30-1997	
	B44	WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
	B45	WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
	B46	WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials <sup>a</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C155	[No Author Listed] CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study Results. 57 <sup>th</sup> Annual Meeting of the American Association for the Study of Liver Diseases. October 27-31, 2006. Boston, MA. 9 pages.	
	C156	AHLUWALIA et al., Immunostimulatory proglins from two classes of CpG ODN administered subcutaneously to healthy subjects. ICI FOCUS 2004.	
	C157	AOKI et al., Use of cytokines in infection. Expert Opin Emerg Drugs. 2004 Nov;9(2):223-36.	
	C158	BOHN et al., Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains. Infect Immun. 1998 May;66(5):2213-20.	
	C159	DE FRANCESCO et al., Challenges and successes in developing new therapies for hepatitis C. Nature. 2005 Aug 18;436(7053):953-60.	
	C160	GRAY et al., CpG-B ODNs potentially induce low levels of IFN- $\alpha$ and induce IFN- $\alpha$ -dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J Leukoc Biol. 2007 Apr;81(4):1075-85. Epub 2007 Jan 16.	

EXAMINER: /Jeffrey Parkin/	DATE CONSIDERED: 09/05/2008
----------------------------	-----------------------------

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  .				APPLICATION NO.: 10/023,909	ATTY. DOCKET NO.: C1039.70058US00
				FILING DATE: December 18, 2001	CONFIRMATION NO.: 8458
				APPLICANT: Davis et al.	
				GROUP ART UNIT: 1648	EXAMINER: Jeffrey S. Parkin
Sheet	2	of	2		

	C161	GREGORIADIS, Immunological adjuvants: a role for liposomes. Immunol Today. 1990 Mar;11(3):89-97.	
	C162	HAHN, Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol. 2003 Aug;15(4):443-9.	
	C163	INFANTE-DUARTE et al., Th1/Th2 balance in infection. Springer Semin Immunopathol. 1999;21(3):317-38.	
	C164	ITO et al., CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect Immun. 2005 Sep;73(9):6154-6.	
	C165	KNIFE et al., eds., Fields' Virology. 2001;1:1004-16; 1127-1161.	
	C166	KRIEG, Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul;4(3):289-94.	
	C167	MARTINSON et al., Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr;120(4):526-35.	
	C168	MASIH et al., Fighting infection using immunomodulatory agents. Expert Opin Biol Ther. 2001 Jul;1(4):641-53.	
	C169	SAKAO et al., IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int Immunol. 1999 Mar;11(3):471-80.	
	C170	WEINER et al., Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotypic antibody and is synergistic with GMCSF. Blood. 1996 Nov 15;88(10):Suppl. 1 pt. 1. Abstract #348.	
	C171	ZAITSEVA et al., Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection. Blood. 2000 Nov 1;96(9):3109-17.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 12870G163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.P./